Semler Scientific, Inc. (NASDAQ:SMLR) Q1 2024 Earnings Call Transcript

Renae Cormier: Yes. We think it will follow a similar cadence where H1 will be more heavily weighted than H2.

Aaron Wukmir: Got it. Very helpful. Thanks for taking my question, again.

Operator: This concludes our question-and-answer session. I’d like to turn the call back over to Renae Cormier for any closing remarks.

Renae Cormier : Thank you. As we wrap up this conference call, we want to emphasize our ongoing commitment to delivering clinical benefits through earlier diagnosis of chronic cardiovascular conditions. The continued recognition of the value of this approach by our customers underscores the crucial role our technology plays for patients, physicians, facilities and payers in an evolving health care landscape. Moving forward, our primary objective remains to preserve and strengthen our current revenue opportunities and profitability within the chronic disease space with a focus on cardiovascular diseases. We appreciate your participation in today’s discussion, and thank you for your ongoing support.

Operator: The conference has now concluded. Thank you for attending today’s presentation, and you may now disconnect.